Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depression in Sleep Apnoea study
ACTRN12621001151820Phase 4Withdrawn
- Sponsor
- WA Centre for Health & Ageing
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of escitalopram in major depressive disorder (MDD) and obstructive sleep apnea hypopnea syndrome (OSAHS) (4 arms), sponsored by WA Centre for Health & Ageing. Primary endpoint: Change in depressive symptoms. Planned start Sep 2021; status: withdrawn.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on ACTRN12621001151820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001151820.